

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/002,211
(use as many sheets as necessary)				Filing Date	12/05/2001
				First Named Inventor	David M. GOLDENBERG
				Group Art Unit	3763
				Examiner Name	Unassigned CHUN CROWDER
				Attorney Docket Number	018733-1066
Sheet	1	of	2		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	B1	4,036,945	A	HABER	07-19-1977	
	B2	4,331,647	A	GOLDENBERG	05-25-1982	
	B3	4,444,744	A	GOLDENBERG	04-24-1984	
	B4	4,735,210	A	GOLDENBERG	04-05-1988	
	B5	5,101,827	A	GOLDENBERG	04-07-1992	
	B6	5,144,807	A	PFAHL	09-01-1992	
	B7	5,152,980	A	STROM et al.	10-06-1992	

considered 8/17/06

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
C.C.	B8	EP	0 217 992	A	BETH ISRAEL HOSPITAL	04-15-1987	
C.C.	B9	EP	0 274 394	A	ONCOGEN	07-13-1988	
	B10	EP	0 330 201	A	NEORX CORPORATION	08-20-1989	
C.C.	B11	WO	83/04313	A	UNIV CALIFORNIA	12-08-1983	
C.C.	B12	WO	89/07601	A	TAN KIM SZE	08-24-1989	
C.C.	B13	WO	91/16069	A	US HEALTH	10-31-1991	
C.C.	B14	WO	93/13805	A	BAGSHAW	07-22-1993	
C.C.	B15	WO	94/10202	A	GENENTECH INC.	05-11-1994	

duplicate considered IDS filed 12/05/01

BEST AVAILABLE COPY

Examiner Signature	<i>ch cf</i>	Date Considered	02/28/07
--------------------	--------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/002,211
				Filing Date	12/05/2001
(use as many sheets as necessary)				First Named Inventor	David M. GOLDENBERG
				Group Art Unit	3763
Sheet 2 of 2				Examiner Name	Unassigned-CHUN
				Attorney Docket Number	018733-1066

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	B10	BOSSLET et al., "Immunohistochemical localization and molecular characteristics of three monoclonal antibody-defined epitopes detectable on carcinoembryonic antigen (CEA)," <u>International Journal of Cancer - Journal International Du Cancer</u> , July 15, 1985, pp. 75-84, Vol. 36, No. 1		
	B17	DELAND et al., "Axillary lymphoscintigraphy by radioimmuno-detection of carcinoembryonic antigen in breast cancer," <u>Journal of Nuclear Medicine</u> , 1979, pp. 1243-1250, Vol. 20, No. 12		Duplicate of IDS filed 12/6/01
	B18	DILHUYDY et al., "Three-dimensional imaging of dual isotope data-sets in a case of acute myocardial infarction," <u>British Journal of Radiology 1992 United Kingdom</u> , March 1992, pp. 273-278, Vol. 65, No. 771		
	B19	DUNCKER et al., "Radioimmune imaging of bone marrow in patients with suspected bone metastases from primary breast cancer," <u>J. Nucl. Med.</u> , 1990, pp. 1450-1455, Vol. 31, No. 9		
	B20	MASUJIMA et al., "Biological component microanalysis by laser photoacoustic imaging immunoassay," <u>Chemical and Pharmaceutical Bulletin (Tokyo)</u> , 1989, pp. 1123-1125, Vol. 37, No. 4		Duplicate
	B21	RESKE et al., "Radioimmunomaging for diagnosis of bone marrow involvement in breast cancer and malignant lymphoma," <u>Lancet</u> , 1989, pp. 299-301, Vol. 1, No. 8633		
	B22	SHARKEY et al., "Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinetic and targeting properties in humans," <u>Cancer Research</u> , 1990, pp. 2823-2831, Vol. 50, No. 9		
	B23	SIEGLE et al., "Development of a model using polypeptide antibodies for scintigraphy of the pancreas," <u>Investigative Radiology</u> , September 1980, pp. 457-461, Vol. 15, No. 5		
	B24	SIGNORE et al., "A radiopharmaceutical for imaging areas of lymphocytic infiltration: Iodine-123 interleukin-2: Labelling procedure and animal studies," <u>Nuclear Medicine Communications</u> , October 1992, pp. 713-722, Vol. 13, No. 10		
	B25	SIGNORE et al., "The in vivo visualization of insulinitis. A new marker of prediabetes," <u>Advances in Experimental Medicine and Biology</u> , 1988, pp. 119-125, Vol. 246		
	B26	TAKEDA et al., "Radioimmunolocalization of the monoclonal antibody J28 in early transformation stages in N-nitrosobis(2-hydroxypropyl)amine-induced pancreatic tumors in the Syrian golden hamster," <u>Journal of Cancer Research and Clinical Oncology</u> , 1992, pp. 377-385, Vol. 118, No. 5		
	B27	VOLPINI et al., "Diagnosis of acute myocardial infarction by indium-111 antimyosin antibodies and correlation with the traditional techniques for the evaluation of extent and localization," <u>The American Journal of Cardiology</u> , January 1, 1989, pp. 7-13, Vol. 63, No. 1		

BEST AVAILABLE COPY

Examiner Signature	<i>h</i> <i>of</i>	Date Considered	03/01/07
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.